Crossmark

Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiency

Crossref DOI link: https://doi.org/10.1186/s12962-024-00600-w

Published Online: 2025-03-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jakobs, F.

Ahmadi, P.

Osterkamp, V.

Jeck, J.

Holtick, U.

Scheid, C.

Kron, Florian
License Information

Text and Data Mining valid from 2025-03-05

Version of Record valid from 2025-03-05
More Information

Article History

Received: 29 August 2023

Accepted: 30 November 2024

First Online: 5 March 2025

Declarations

:

: Due to the retrospective study design and a pseudonymised documentation of underlying cost data, no ethical vote was needed.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below